You are here

  • Home
  • Archive
  • Volume 20, Issue 4
  • Serum Vascular Endothelial Growth Factor and Adiponectin Levels in Patients With Benign and Malignant Gynecological Diseases

Article Text

Article menu
Download PDFPDF
Original Article
Serum Vascular Endothelial Growth Factor and Adiponectin Levels in Patients With Benign and Malignant Gynecological Diseases
  1. Carla Lasalandra, PhD*,
  2. Maria Coviello*,
  3. Gaetano Falco, MD†,
  4. Rosa Divella*,
  5. Giuseppe Trojano, MD†,
  6. Anna Maria Laterza*,
  7. Carmela Quero, MD*,
  8. Vito Pepe, MD‡,
  9. Francesco Alfredo Zito, MD* and
  10. Michele Quaranta, MD*
  1. *Departments of Experimental Oncology, and
  2. †Departments of Gynaecologic Oncology, Giovanni Paolo II, National Cancer Institute, Bari; and
  3. ‡Departments of Department of Nephrology, S. Maria degli Angeli Hospital, Putignano, Bari, Italy.
  1. Address correspondence and reprint requests to Carla Lasalandra, PhD, Via A. Gabrieli 7, 70125 Bari, Italy. E-mail: carla_lasalandra{at}virgilio.it.

Abstract

Introduction: One of the most specific and critical regulators of angiogenesis is vascular endothelial growth factor (VEGF), which regulates endothelial proliferation, permeability, and survival. Vascular endothelial growth factor is an angiogenic mediator in tumors and has been implicated in the pathogenesis and progression of cancer. Adipose tissue is a major endocrine and it secretes hormones termed adipokines. These factors are derived from adipocytes and include proteins and metabolites such as adiponectin. Recently, adiponectin was also shown to modulate angiogenesis. This study was designed to determine the serum VEGF and adiponectin levels in patients with benign and malignant gynecological diseases and if there was a correlation between serum VEGF and adiponectin.

Methods: Serum samples, collected fasting before surgery or intervention, were available for total of 114 female patients recorded between October 2006 and December 2008. Diagnosis of benign and malignant gynaecological diseases was established by biopsy. Serum levels VEGF and adiponectin were using commercially available enzyme linked immunosorbent assay (R&D Systems Inc, Minneapolis, MN), respectively. Statistical analysis was performed by using the SPSS 9.0 software package (SPSS, Inc, Chicago, IL). The correlation between serum VEGF and serum Adiponectin was calculated using the Pearson correlation coefficient. P values of < 0.05 were considered statistically significant.

Results: Our results were analyzed on the basis of 2 different parameters: age and benign and malignant gynecological diseases of the patient. Only for serum VEGF levels was a significant difference observed (P = 0.004) between patients with benign and malignant gynecological diseases. A significantly inverse correlation between serum VEGF and adiponectin levels among patients with benign and malignant gynecological diseases was found. Adiponectin level is not correlated with body mass index.

Conclusions: This is one of the first report on adiponectin in benign and malignant gynecological diseases. Future studies are needed to address the clinical potential role of adiponectin in cancer.

  • Gynecological disease
  • VEGF
  • Adiponectin
  • Angiogenesis

https://doi.org/10.1111/IGC.0b013e3181c54fc5

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.